STAA
STAAR Surgical Co
$63.62
Earnings Summary
Revenue | $63.2Mn |
Net Profits | $9.6Mn |
Net Profit Margins | 15.19% |
Highlights
STAAR Surgical Co’s revenue jumped 24.53% since last year same period to $63.2Mn in the Q2 2022. On a quarterly growth basis, STAAR Surgical Co has generated 7.12% jump in its revenue since last 3-months.
STAAR Surgical Co’s net profit jumped 92.35% since last year same period to $9.6Mn in the Q2 2022. On a quarterly growth basis, STAAR Surgical Co has generated 95.08% jump in its net profits since last 3-months.
STAAR Surgical Co’s net profit margin jumped 54.46% since last year same period to 15.19% in the Q2 2022. On a quarterly growth basis, STAAR Surgical Co has generated 82.12% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the STAAR Surgical Co post its latest quarter earnings
EPS Estimate Current Quarter | 0.08 |
EPS Estimate Current Year | 0.08 |
Highlights
STAAR Surgical Co’s earning per share (EPS) estimates for the current quarter stand at 0.08 - a -38.46% fall from last quarter’s estimates.
STAAR Surgical Co’s earning per share (EPS) estimates for the current year stand at 0.08.
Key Ratios
Key ratios of the STAAR Surgical Co post its Q1 2023 earnings
Return on Assets (ROA) | 0.07 |
Return on Equity (ROE) | 0.13 |
Highlights
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. STAAR Surgical Co’s return on assets (ROA) stands at 0.07.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. STAAR Surgical Co’s return on equity (ROE) stands at 0.13.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2017-05-03 | -0.04 | -0.05 | -25% |
2017-03-02 | -0.02 | 0.02 | 200% |
2017-08-02 | -0.03 | -0.02 | 33.33% |
2017-11-08 | -0.03 | 0.03 | 200% |
Company Information
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or 'ICL', which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland.
Organisation | STAAR Surgical Co |
Headquarters | 25651 Atlantic Ocean Drive, Lake Forest, CA, United States, 92630 |
Employees | 882 |
Industry | Health Technology |
CEO | Caren Mason |
